Precipio (NASDAQ:PRPO) Shares Cross Below 200 Day Moving Average – Here’s Why

Precipio, Inc. (NASDAQ:PRPO) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $25.17 and traded as low as $22.95. Precipio shares last traded at $25.24, with a volume of 170,506 shares traded.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a report on Tuesday, April 21st. Wall Street Zen lowered Precipio from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Precipio currently has a consensus rating of “Sell”.

Precipio Stock Up 4.1%

The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.33 and a current ratio of 1.56. The firm’s 50-day moving average is $24.29 and its 200 day moving average is $25.17. The firm has a market capitalization of $44.11 million, a PE ratio of -52.43 and a beta of 1.27.

Precipio (NASDAQ:PRPO) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.81) earnings per share for the quarter. Precipio had a negative return on equity of 6.73% and a negative net margin of 3.57%.The business had revenue of $6.71 million for the quarter.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Susquehanna International Group LLP acquired a new position in shares of Precipio during the 3rd quarter valued at about $194,000. Geode Capital Management LLC grew its stake in shares of Precipio by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after buying an additional 789 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in shares of Precipio by 10.7% during the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after buying an additional 1,400 shares during the last quarter. Hedge funds and other institutional investors own 10.45% of the company’s stock.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.